Compass Therapeutics Investor Presentation Deck

CTX-009-Vision and Potential 88 Best-in-class DLL4 x VEGF- A bispecific Phase 2/3 nearing initiation with ongoing Phase 2 parallel development in S. Korea and China COMPASS THERAPEUTICS Oncology Has demonstrated compelling activity in the 3rd line and 4th line settings in patients with Cholangiocarcinoma, Colorectal Cancer, Gastric Cancer and Pancreatic Cancer Could become front line therapy in multiple solid tumors Other potential indications based on DLL4 expression such as Ovarian Cancer & Renal Cell Ophthalmology Potential to address AMD and DME based on mechanism Consideration for partnership 8

View entire presentation